Home › Studies › PRJNA672867

PRJNA672867 SRP292135

FMT with anti-PD-1 therapy in melanoma, Pittsburgh adults

Effectiveness of Fecal Microbiota Transplant together with PD-1 blockade in overcoming resistance to anti-PD-1 therapy in advanced melanoma patients

216 fecal samples from adult and elderly melanoma patients and donors in Pittsburgh, USA, studying fecal microbiota transplant combined with PD-1 blockade drug therapy in an intervention design. machine-written summary

216 samples · 216 runs · US · Adult · 2020 · 2.19 Gbp / sample · cohort Dietary fiber and probiotics influence the gut mic

ENA BioProject Sample sheet Registry Download Flag an issue

Sources

✓Sequence archive 2,841○Abstract / description○Full text✓Supplementary tables 183–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave

✓ Sequence archive	2,841 sample values (age, collection date, country, health condition, health condition detail, intervention, intervention detail, latitude)
○ Abstract / description	read; no usable statement
○ Full text	read; no usable statement or table · PMC8097968, PMC9477264
✓ Supplementary tables	183 sample values (subject id)
– External resources	not covered by the external resources we ingest
– User contribution	nothing uploaded yet
– Human verified	not yet checked by a person · I checked this project — verify it

Interventions

intervention · arms resolved

single arm: samples before and on the intervention

15 people have samples in more than one arm.

Non-antibiotic pharmaceutical given as the study intervention (metformin Faecal microbiota transplantation design single_arm_before_after · population other_cancer · Responder-derived FMT combined with anti-PD-1 therapy in refractory melanoma

“responder-derived fecal microbiota transplantation (FMT) together with anti-PD-1” — abstract:33542131 (study level; per-sample arms are in the intervention column below)

Samples at a glance

1 sampling locations · 1 country

Age

adult134

elderly82

Condition

other_cancer216

Sex

male151

female65

Country

US216

Body site

primary216

Collected 2018–2020

Sequencing depth per sample · this project all projects

Sampling design and relatedness

longitudinalFMT donor → recipient

24 of 33 people sampled more than once (207 samples; median 6, up to 35 per person) · follow-up median 6 mo (max 2.0 y) · median interval between samples 8 d (time from collection dates). Schedule stated by the source: “Pre-FMT (7 to 21 days prior FMT) and longitudinal post-FMT (weekly collected for 12 weeks and then every 3 weeks, if available), up to 535 days post FMT” (time origin: transplant); stated follow-up 18 mo.

Each row is one person (24 shown); dots are samples at days since that person's first sample.

FMT + anti-PD-1: 15 recipients linked to 7 sampled donors via Donor_ID; 18 donor IDs sampled.

donorrecipient · circles are people (pale = no sequenced sample), arrows run donor → recipient and parent → child, curved lines join twins, partners and siblings, squares are shared settings or families without recorded roles. Shown: 7 linked groups from explicit relations. 33 people in the project overall.

How longitudinal and relatedness information is derived

Community composition

Bacteroides 21.4%Alistipes 12.6%Phocaeicola 9.3%Prevotella 5.0%Akkermansia 4.0%Parabacteroides 2.9%Roseburia 2.4%Faecalibacterium 2.1%Vescimonas 2.0%Barnesiella 1.6%Porphyromonas 1.6%Escherichia 1.1%not assigned to a genus 8.6%other genera 25.5%

Genera, mean relative abundance over 191 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).

Field coverage

field	samples	coverage	R1	R2
age_category	216	100%
country	216	100%	216
health_condition	216	100%	216
subject_id	216	100%	33	183
age_at_collection_days	216	100%	216
collection_date	216	100%	216
detailed_location	216	100%
health_condition_detail	216	100%	216
intervention	216	100%	216
intervention_detail	216	100%	216
latitude	216	100%	216
location_locality	216	100%	216
location_region	216	100%	216
longitude	216	100%	216
sex	216	100%	216
timepoint_label	216	100%	216

Papers (13)

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. 2021 PMID 33542131 PMC8097968 own_data
Time series strain tracking analysis post fecal transplantation identifies individual specific patterns of fecal dominant donor, recipient, and unrelated microbial strains. 2022 PMID 36107983 PMC9477264 own_data
Incongruence between dominant commensal donor microbes in recipient feces post fecal transplant and response to anti-PD-1 immunotherapy. 2021 PMID 34544375 PMC8454007 unsure
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. 2021 PMID 34941392 PMC8970537 unsure
The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. 2022 PMID 36083892 PMC9925043 unsure

8 more

Consistent Stool Metagenomic Biomarkers Associated with the Response To Melanoma Immunotherapy. 2023 PMID 36809182 PMC10134792
Recipient-independent, high-accuracy FMT-response prediction and optimization in mice and humans. 2023 PMID 37580821 PMC10424414
Systemic metabolic depletion of gut microbiome undermines responsiveness to melanoma immunotherapy. 2024 PMID 38448159 PMC10917649
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. 2024 PMID 39481388 PMC11629153
Engrafting gut bacteriophages have potential to modulate microbial metabolism in fecal microbiota transplantation. 2025 PMID 40542451 PMC12180181
Ecological and Functional Stratification of the Stool Microbiome Predicts Response to Immune Checkpoint Inhibitors across Cancer Types. 2026 PMID 42146906 PMC13173278
Enterotype-specific microbial biomarkers of immune checkpoint inhibitor response revealed by large-scale integrated metagenomic analysis. 2026 PMID 42189287 PMC13388844
Cohesive modules of engraftment in fecal microbiota transplantation. 2026 PMID 42211136 PMC13213781

Details

Archive description

This study set out to evaluate the effectiveness of Fecal Microbiota Transplant together with PD-1 blockade in overcoming resistance to anti-PD-1 therapy in advanced melanoma patients.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of adult and elderly by deterministic_prior with confidence 0.90. Assay shotgun_dna.

host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
body site study.title · “Effectiveness of Fecal Microbiota Transplant together”
body site study.description · “the effectiveness of Fecal Microbiota Transplant together”
life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
life stage sample.attr.age · “62 (n=124/216)”

Evidence examples (one per field × route)

sample	field	value	route	conf.	source	quote
SAMN16673179	age_at_collection_days	21549.8	R1	0.70	sample.attr.age	59
SAMN16673179	collection_date	2019-08-06	R1	0.90	biosample.attribute:collection_date	2019-08-06
SAMN16673179	country	US	R1	0.90	sample.attr.geo_loc_name	USA: Pittsburgh
SAMN16673179	health_condition	other_cancer	R1	0.85	biosample.attribute:donor_or_recipient	Recipient
SAMN16673179	health_condition_detail	advanced melanoma, PD-1-refractory, receiving FMT + anti-PD-1 per title 'Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients' and abstract 'patients with PD-1-re	R1	0.85	biosample.attribute:donor_or_recipient	Recipient
SAMN16673179	intervention	fmt	R1	0.90	biosample.attribute:Pre_or_post_FMT	Pre_or_post_FMT: Post_FMT
SAMN16673179	intervention_detail	post-FMT sample	R1	0.90	biosample.attribute:Pre_or_post_FMT	Pre_or_post_FMT: Post_FMT
SAMN16673179	latitude	40.4540	R1	0.90	biosample.attribute:lat_lon	40.454 N 79.933 W
SAMN16673179	location_locality	Pittsburgh	R1	0.85	biosample.attribute:geo_loc_name	USA: Pittsburgh
SAMN16673179	location_region	Pennsylvania	R1	0.60	biosample.attribute:lat_lon	40.454 N 79.933 W
SAMN16673179	longitude	-79.9330	R1	0.90	biosample.attribute:lat_lon	40.454 N 79.933 W
SAMN16673179	sex	male	R1	0.90	sample.attr.sex	male
SAMN16673189	subject_id	PT-18-0005	R1	0.85	sample.attr.donor_id	PT-18-0005
SAMN16673179	subject_id	PT-19-0002	R2	0.80	archive
SAMN16673179	timepoint_label	85	R1	0.85	sample.attr.days_after_fmt	85

Sequencing

216 runs over 216 samples · mean 2.32 Gbp per run (median 2.19 Gbp, total 500.34 Gbp; 216 runs with a base count) · layout PAIRED 216 · platform ILLUMINA 216 · models Illumina NovaSeq 6000 (186), NextSeq 500 (30) · 88% of runs with a Sandpiper profile · first public 2020-12-03

Authors (40)

Koo H first · Morrow CD last · Zakharevich NV first · Morozov MD · Kanaeva VA · Filippov MS · Zyubko TI · Ivanov AB · Ulyantsev VI · Klimina KM · Olekhnovich EI last · Tarracchini C first · Lugli GA · Mancabelli L · van Sinderen D · Turroni F · Ventura M · Milani C last · Orletskaia VA first · Candeliere F first · Busi E · Cerri S · Sola L · Lombardi M · Greco S · Pedroni S · Amaretti A · Raimondi S · Chiavelli C · Vitale MG · Bertolini F · Depenni R · Franchini G · Dominici M · Rossi M last · Rashidi A first · Minot SS · Lee SJ · Hill GR · Podlesny D last

Downloads

PRJNA672867.csv.gz (8.7 KB) · parquet (82.7 KB) — all 216 samples, every field with route and confidence · PRJNA672867_determinations.csv.gz (24.5 KB) — 3,024 evidence rows

Samples (216 · every field this project has values for · hover a cell for its source)

Loading the sample table…